MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery.

Trial Profile

MEND-CABG II: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG Surgery.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2008

At a glance

  • Drugs Pyridoxal phosphate; Pyridoxal phosphate
  • Indications Myocardial ischaemia; Myocardial reperfusion injury; Perioperative ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms MEND-CABG-II
  • Sponsors Medicure
  • Most Recent Events

    • 01 Apr 2008 Results published online (JAMA) and presented at ACC 2008
    • 04 Mar 2008 Primary endpoint not met, as reported by Medicure in a media release.
    • 15 Nov 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top